Now, it's important to remember that while Lue was on the staff of another one of those head coaches who has a championship ring, Doc Rivers, he's a little bit different. That seemingly caused tension within the ranks, an issue that came further into the light with reports on the hiring of Tyronn Lue as the team's next head coach.
These are some of the things that new head coach Tyronn Lue will inherit, the Los Angeles Times reported. Lue was able to work with Kevin Love and helped the power forward achieve his potential by becoming an integral part of the 2016 team. And because he was a point guard, he was going to look for a lot of leadership on the floor.
Lue owns a 128-83 record as an National Basketball Association head coach.
There were signs of contention inside the Clippers locker room throughout the season.
Lue had served as an assistant on Rivers' staff, and has familiarity with the team's personnel. They're going to have some personnel issues to fix, because it wasn't just coaching that doomed the Clippers.
"They clearly need a point guard".
Nick Nurse on coaching through unprecedented times1 day ago7:59
Now, Lue will be one to embrace a little bit of conflict. However, these never really came out in the open, with most using the Clips' meltdown in the National Basketball Association playoffs to back up that claim.
That will not be easy to find, especially after the Clippers gave up multiple first-round picks to acquire Paul George last offseason. During a segment on First Take recently, Stephen A. Smith made the claim that Kawhi Leonard has been active in trying to improve this roster.
According to BetOnline, the Clippers have the second-best odds to win the championship next season.
Lue was in his second stint with the Clippers, having joined them initially in July 2013.
It is known to everyone how the Clippers went up from #8 in 2019 to #2 in 2020 regular-season.
The race for a Covid-19 vaccine heats up
Fears of delays were raised after trials for two rival vaccines were put on hold in the United States in recent weeks. Three were in Moderna's trial, while the other two were in Pfizer's.